It should not come as a surprise to anyone who has read Dr. Paul Kalanithi’s brilliant—and unforgettable—memoir, When Breath Becomes Air (Random House, 2016), that nearly a year after publication, it remains on The New York Times best-seller list, its popularity only increasing with time. Written...
Next to me sounds the buzzing of my Lympha Press machine, which substitutes for the constant visits of the physiotherapist who performs the lymph drainage. This gives me more freedom, and we have more privacy at home. I can use the machine whenever I need it, and my 5-year-old daughter, Christina, ...
The 2016 European Society for Medical Oncology (ESMO) Congress revealed many important positive findings from key trials in a number of tumor types, but many highly anticipated phase III trials in advanced disease failed to meet their primary endpoints. The ASCO Post has summarized several of these ...
In 2016 and 2017, a team from The Ralph Lauren Center for Cancer Care (RLCCC) is participating in an ASCO Quality Improvement Grant program, which is supported by the Stavros Niarchos Foundation. The grant program aims to improve the delivery of cancer care in medically underserved communities by...
The current plethora of drugs in development for oncology is leading to the testing of novel agents in common as well as rare diseases. Targeted therapies have been a focus of great interest in soft-tissue sarcomas, with testing of a variety of oral tyrosine kinase inhibitors leading to the...
Earlier this year, Sean Parker, the cofounder of the music streaming service Napster and an early president of Facebook, joined a growing list of entrepreneurs who are committing large portions of their wealth to funding cancer research. In April, Mr. Parker announced he was donating $250 million...
As reviewed in this issue of The ASCO Post, Brian Rini, MD, and colleagues recently reported results from the phase III IMPRINT trial,1 which randomized HLA-A*02–positive patients with treatment-naive metastatic clear cell variant renal cell carcinoma, in favorable- and intermediate- risk...
We are in the midst of a paradigm shift in lung cancer. In the past 2 years, the anti–programmed cell death protein 1 (anti–PD-1) inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) were found to improve overall survival in the second-line setting compared with docetaxel for patients with...
Fred Hutchinson Cancer Research Center (Fred Hutch) has announced the official opening of a first-of-its-kind clinic dedicated to providing immunotherapies for cancer patients in clinical trials. The Bezos Family Immunotherapy Clinic, named in recognition of a family that has been deeply committed...
Blocking a molecule may bypass bowel cancer's defense against the drug cetuximab, according to new research presented by Weir et al at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, United Kingdom. Cetuximab is used to treat advanced bowel cancer, and just under half ...
I still remember the day I met Kensie. It was Valentine’s Day. I had sneaked out of the hospital to get my wife a Valentine’s Day card, taking my place among scores of other husbands and boyfriends in front of the rapidly emptying rack of cards. As I started browsing, my beeper sounded. It was the ...
Nonrhabdomyosarcoma soft-tissue sarcomas account for about 5% of all childhood malignancies and are also diagnosed in adolescents and young adults, as well as in older adults, and can require different approaches to treatment based on a patient’s age and stage of disease. These sarcomas comprise...
ASCO Connection: Why do you want to serve as ASCO President? Monica Bertagnolli: Serving as ASCO President is a tremendous personal honor for anyone in the field of oncology. Much more importantly, it is an opportunity to make a meaningful difference by providing a strong voice in the health-care ...
In a spirited debate, abounding with citations of clinical trials and other evidence, but not without humor and mutual respect, E. Shelley Hwang, MD, MPH, and Armando E. Giuliano, MD, reviewed the data and their clinical experience managing ductal carcinoma in situ and reached opposite...
The successes observed with various immune oncologic treatment approaches have largely bypassed pancreatic cancer, but this may be about to change, based on emerging insights into how and why these tumors evade attacks by T cells. At the 2nd International Cancer Immunotherapy Conference, two...
A number of lung cancer specialists were anxious to comment on the positive findings of KEYNOTE-024 and were equally perplexed about the negative results of CheckMate-026. All agreed that the overall survival benefit makes pembrolizumab (Keytruda) a game-changer for the first-line treatment of...
Scientists have measured the genetic damage caused by smoking in different organs of the body and identified several different mechanisms by which tobacco smoking causes mutations in DNA. Researchers at the Wellcome Trust Sanger Institute, the Los Alamos National Laboratory, and their collaborators ...
As expensive cancer biologics move off patent, biosimilar products are coming on board. These are highly similar versions of licensed biologics that demonstrate near-fingerprint identity to their reference products in terms of structure and potency. Biosimilars represent a major opportunity for...
When I lost my only sister to breast cancer in 1986, patients like her had devastatingly few choices. Over the intervening decades, sustained commitment to biomedical research at the National Institutes of Health (NIH) and major technologic advances have led to transformative changes in cancer...
On October 14, 2016, the Centers for Medicare & Medicaid Services (CMS) announced its final policy on what physicians need to do to begin implementing the Quality Payment Program outlined in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The Quality Payment Program is a...
A study by University of North Carolina (UNC) Lineberger Comprehensive Cancer Center researchers has found that younger, uninsured women in North Carolina had higher odds of missing a 60-day window for getting follow-up after an abnormal mammogram, even though research underscores the importance of ...
Painful sex in women after cancer treatment is relatively common, often treatable, and needs to be addressed by medical providers, a University of California (UC), Davis, oncologist and researcher suggests. Vanessa Kennedy, MD, a gynecologic oncologist at UC Davis Health System, said that with...
Although clinical trials are helpful in determining the effectiveness of a specific drug across a patient population, they are not as reliable at pinpointing how well a particular patient will respond to the drug or dosing regimen or how the drug may impact the patient’s quality of life from...
Perhaps more than any other book in recent memory, When Breath Becomes Air has struck a chord among readers, both inside the medical community and among the public, desiring an honest and philosophical consideration of death. The autobiographical account of Paul Kalanithi, MD, a physician diagnosed ...
Andrés Cervantes, MD, PhD, Scientific Chair of the 2016 European Society for Medical Oncology (ESMO) Congress, concluded the meeting earlier this month by recognizing a number of important take-home messages. At a closing press conference, Dr. Cervantes noted that the “ESMO 2016 Congress has...
Uveal melanoma is the second most common type of skin cancer. Approximately 50% of patients with uveal melanoma will develop metastasis, most commonly to the liver. The disease can appear more than 10 years after the primary lesion has been removed, lying dormant for long periods. There are...
The treatment of cancer of the larynx has changed dramatically in recent years. With organ preservation now possible in many cases, it is more important than ever for patients to receive guidance from every corner of the field. In a recent article in the Journal of Oncology Practice (JOP),1 a...
The Avon Foundation for Women recently released a new study on the racial disparities in breast cancer mortality in the 50 largest cities in the United States between 2005 and 2014. Published in Cancer Epidemiology,1 the study was conducted by Sinai Urban Health Institute in collaboration with the...
Nintedanib (Ofev) improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to the results of the phase III LUME-colon 1 trial presented by Van Cutsem et al at the 2016 European Society of...
The advent of more effective systemic therapies, which extend patients’ lives, has also resulted in an increasing incidence of brain metastases, for which clinicians must determine appropriate treatment. Whole-brain radiotherapy has been the traditional treatment modality, but stereotactic...
The Susan G. Komen breast cancer organization gathered philanthropic, civic, medical, and business leaders in Washington, DC, September 14 to formally launch a $27 million, 10-city initiative to reduce breast cancer death rates among African American women. “African American women are almost 40%...
Caregivers of patients with cancer provide invaluable health-care services, but they are an underserved and undervalued group, with many unmet needs. Early palliative care may provide important benefits to these often tireless individuals, according to J. Nicholas Dionne-Odom, PhD, RN, ACHPN, of...
A session at the 2016 Palliative Care in Oncology Symposium focused on the special needs of cancer caregivers. In a large survey, caregivers of persons with cancer reported higher levels of stress and significantly more duties than caregivers of other patients. But, according to research from...
The advent of immunotherapies has created a number of interesting challenges for oncology providers. At the 2016 Palliative Care in Oncology Symposium, specialists in the field tackled these issues. “There is a lot of newness to how we approach patient care with immunotherapies on board,” said...
This past summer, Eric S. Lander, PhD, President of the Broad Institute of the Massachusetts Institute of Technology and Harvard in Cambridge, Massachusetts, and Co-Chair of the President’s Council of Advisors on Science and Technology, raised a few eyebrows at the Aspen Ideas Festival when he...
The third annual Palliative Care in Oncology Symposium, held on September 9–10, 2016, in San Francisco, California, brought together more than 650 attendees from multiple countries, including the United States, Canada, the United Kingdom, France, Italy, and China. It featured over 250 study...
Although research advances in more effective therapies and diagnostics and improved screening technology over the past 2 decades have led to a 23% reduction in the cancer death rate in the United States, saving nearly 2 million lives,1 cancer remains the second leading cause of death after heart...
Even though I was just 3 years old when my symptoms first appeared, the memory is still fresh in my mind to this day, 71 years later. I had just come home from a friend’s birthday party and was sitting on the front patio steps immobilized by severe stomach pain. My parents said I was feeling ill...
There have been numerous books explicating the information a physician or patient needs to know about our current clinical state in the diagnosis and treatment of ovarian cancer. Many of them are good, but rare is a well-written book in the cancer genre that offers solid scientific hope exceeding ...
Earlier this month, members of the National Cancer Moonshot Initiative’s Blue Ribbon Panel submitted an ambitious list of 10 recommendations on the scientific approaches that are most likely to accelerate progress against cancer to the President’s National Cancer Advisory Board. The panel’s...
Studies show that adolescent and young adult cancer survivors experience distinct challenges and quality-of-life issues from those experienced by either younger or older adult cancer survivors and that those challenges and issues can persist long after the cancer diagnosis and the end of...
A new study1 showing that just 1 in 20 terminally ill patients with cancer has sufficient understanding about the prognosis or purpose of treatment is highlighting the need for improvements in both the way oncologists communicate prognosis with their patients and in the development of educational...
A recent study1 published in the Journal of Clinical Oncology (see “Breaking the ‘Conspiracy of Silence’” in this issue of The ASCO Post) found that just 1 in 20 patients with advanced, incurable cancer has sufficient understanding of his or her prognosis or life expectancy. Now, another new study ...
Cervical cancer incidence and mortality rates—perhaps more than any other chronic disease—shine a grim spotlight on global disparities of care. It is one of the most preventable of human malignancies, yet it is the leading cause of cancer deaths in women around the world. It kills 260,000 women...
Clinicians face a number of questions in evaluating and treating patients with stage IIIA non–small cell lung cancer (NSCLC). One expert in the field, Rafael Santana-Davila, MD, reviewed key issues in managing this disease in the Journal of Oncology Practice (JOP). The ASCO Post asked Dr....
The study findings by Dr. Buchakjian and colleagues suggest it may be time to revisit the significance of frozen margin status, according to one of the session co-moderators, Allen Cheng, MD, DDS, of the Providence Cancer Center and Head & Neck Surgical Associates, both in Portland, Oregon....
As reported in the Journal of Clinical Oncology, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, and colleagues have provided a summary of the groundwork of an initiative by ASCO and the Association of American Cancer Institutes (AACI) to identify and reduce...
The Chinese Journal of Cancer (CJC) is soliciting the 150 most important questions in cancer research and clinical oncology from cancer researchers around the world. The editors of CJC believe this will help provide important insights and guidance in future efforts to advance cancer research...
As reported in the Journal of Clinical Oncology, Vose et al have provided a summary of the groundwork of an initiative by ASCO and the Association of American Cancer Institutes (AACI) to identify and reduce administrative and regulatory burdens in the conduct of cancer clinical trials. The...
In 2012, my husband, Robert, and I were looking forward to starting the next phase of our lives and were feeling excited about the future. Although only in our 50s, we had decided to retire early from our full-time careers, move to our cabin in Hayward, Wisconsin, and find less stressful part-time ...